-
Biogen Soars As FDA Accepts Alzheimer's Drug For Review In 'Next Stage Of Aducanumab Saga'
Friday, August 7, 2020 - 11:40am | 593Read More...Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's drug aducanumab — a drug for which the company halted studies at one point last year — could finally see the light of day. What Happened: The FDA accepted the aducanumab biologics license application for priority...
-
Some Biogen Analysts Unimpressed By Explanation For Aducanumab Filing Delay
Thursday, April 23, 2020 - 3:49pm | 785Read More...Biogen Inc (NASDAQ: BIIB) shares shed close to 10% Wednesday following the revelation that the BLA filing for the company's Alzheimer's investigational drug aducanumab will be delayed. The Biogen Analysts Barclays analyst Carter Gould maintained an Overweight rating on Biogen...
-
Biogen Delays Regulatory Filing For Approval Of Alzheimer's Drug, Shares Slump
Wednesday, April 22, 2020 - 10:23am | 368Read More...Biogen Inc (NASDAQ: BIIB) shares were under pressure Wednesday following the release of the biotech's first-quarter report, including the statement that Biogen's BLA filing for its Alzheimer's drug will be delayed. Issuing an update on the regulatory filing for the Alzheimer's...
-
Biogen's Alzheimer's Drug Has 'Decent Shot' At FDA Approval, Analyst Says
Monday, January 27, 2020 - 12:18pm | 403Read More...Despite the controversy surrounding Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug trial results and skepticism concerning its approvability, an analyst at Canaccord Genuity sounds upbeat. The Analyst Sumant Kulkarni upgraded Biogen from Hold to Buy and increased the price target from $305 to...
-
Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation
Friday, December 6, 2019 - 10:55am | 691Read More...Following Biogen Inc's (NASDAQ: BIIB) presentation of detailed top-line results for aducanumab at the Alzheimer's conference, the stock ended Thursday's session up about 3.5%. The presentation polarized analysts and clinicians alike, stirring a debate on whether the data is sufficient...
-
Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response
Thursday, December 5, 2019 - 3:01pm | 594Read More...Biogen Inc's (NASDAQ: BIIB) presentation of aducanumab data at the Clinical Trials On Alzheimer's Disease Congress has drawn a mixed response. In late October, Biogen announced plans to revive its Alzheimer's program following a new analysis conducted by the company in consultation...
-
Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade
Monday, December 2, 2019 - 2:55pm | 413Read More...Biogen Inc (NASDAQ: BIIB) shares gained more than 25% earlier this year when the company said it planned a regulatory filing for its Alzheimer's drug aducanumab following a new data analysis. Ahead of the Dec. 5 presentation of aducanumab data at the Clinical Trials on Alzheimer'...
-
Cramer Makes The Case Why Biogen's Stock Could Double In Value
Thursday, October 31, 2019 - 1:57pm | 350Read More...Biotech company Biogen Inc (NASDAQ: BIIB)'s once-failed Alzheimer's drug, aducanumab, re-emerged Oct. 22, and this creates a path for the stock to double in size, according to CNBC's Jim Cramer. What Happened Biogen resumed testing aducanumab, and results from a larger dataset in...
-
Biogen Analysts Debate About-Face On Aducanumab: 'Path To Market An Uphill Battle'
Wednesday, October 23, 2019 - 11:37am | 929Read More...Biogen Inc (NASDAQ: BIIB) shares rallied strongly Tuesday after the biotech said it plans a regulatory filing for its Alzheimer's drug aducanumab, which the company had written off back in March. The Analysts Morgan Stanley analyst Matthew Harrison maintained an Underweight rating on...
-
Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'
Friday, March 22, 2019 - 1:30pm | 595Read More...Biogen Inc (NASDAQ: BIIB) shares plunged nearly 30 percent Thursday after, along with development partner Eisai Co., Ltd (OTC: ESALY) announced the decision to scrap two late-stage trials evaluating their Alzheimer's candidate aducanumab. The Analysts Mizuho Securities analyst Salim Syed...
-
Biogen Plunges 25% After Company Discontinues Alzheimer's Drug Study
Thursday, March 21, 2019 - 8:17am | 348Read More...Shares of neuroscience company Biogen Inc (NASDAQ: BIIB) lost more than 25 percent Thursday morning after the company said it will discontinue an ongoing Alzheimer's drug study. What Happened Biogen and its partner Japan-based Eisai said they will discontinue an ongoing global Phase 3...
-
After Biogen's Alzheimer's Update, Wall Street Reacts
Friday, July 6, 2018 - 1:27pm | 643Read More...Biogen Inc (NASDAQ: BIIB) and its Japanese partner Eisai disclosed encouraging results from an 18-month Phase 2 study of its Alzheimer's therapy BAN2401. Here's how some Street analysts reacted to the news. The Analysts Raymond James' Laura Chico maintained a Market...
-
Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs
Friday, February 16, 2018 - 10:37am | 360Read More...Biogen Inc (NASDAQ: BIIB) tumbled 8 percent Wednesday after announcing a cohort expansion for its aducanumab Alzheimer’s trials — a change certain to delay results. The news, coupled with expected sales declines, has converted one analyst from an advocate to an observer. The Rating...
-
Biogen's Best-In-Class R&D Earn Makes It A Buy
Tuesday, October 17, 2017 - 11:35am | 363Read More...Analysts at Stifel turned bullish on Biogen Inc (NASDAQ: BIIB) for four key reasons. The firm's Thomas Shrader upgrades Biogen's stock from Hold to Buy with a price target boosted from $300 to $415. First, there have been no news reports on the "gigantic" aducanumab phase 3 trial, which started in...
-
Biogen's Core Business Impresses While Potential Alzheimer's Catalyst Looms
Thursday, October 5, 2017 - 10:54am | 331Read More...Analysts at Morgan Stanley turned bullish on Biogen Inc (NASDAQ: BIIB) as the company's phase 3 Alzheimer's catalyst could "make all its potential issues disappear." The firm's Matthew Harrison upgraded Biogen's stock rating from Equal-Weight to Overweight with a price target boosted from $311 to $...
